PXD028593-1

PXD028593 is an original dataset announced via ProteomeXchange.

Title	(Phospho)-proteomic characterization of longitudinal biopsies from HCC patients treated with sorafenib
Description	Tumor response rates to targeted therapy are generally low. This poses an urgent medical need to identify molecular mechanisms that determine responsiveness, to inform drug development and therapy. Here, we performed a proteomics and phospho-proteomics (p)proteomics analysis on longitudinal tumor biopsies from eight hepatocellular carcinoma (HCC) patients treated with sorafenib. Three of the patients were responders (group R) and five were nonresponders (group NR). Importantly, the patients clustered by therapy response based on proteomics and p-proteomics data. NR tumors showed increased EMT, glycogen storage, splicing and mitochondrial translation, and decreased carbohydrate metabolism. Furthermore, resistance did not correlate with mTOR signaling but with increased MAPK and decreased AMPK pathway activity. Additionally, phosphorylation of uncharacterized sites (p-sites) in NOTCH pathway components might promote resistance. Our findings suggest potential novel biomarkers for sorafenib-resistant HCC.
HostingRepository	PRIDE
AnnounceDate	2026-05-01
AnnouncementXML	Submission_2026-05-01_12:29:16.716.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Eva Dazert
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	6x(13)C; 6x(13)C; phosphorylated residue
Instrument	Q Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2021-09-16 22:27:54	ID requested
⏵ 1	2026-05-01 12:29:18	announced

10.1073/pnas.1523434113;

10.1186/s12943-026-02604-x;

Boot GF, Haak F, Coto-Llerena M, Boldanova T, Dazert E, Sedlaczek P, Rosenberger G, Esposito C, Ercan C, Wieland S, Renne SL, Benjak A, Matter MS, Di Tommaso L, Hall MN, Terracciano LM, Heim MH, Piscuoglio S, Ng CKY, Multi-omics profiling reveals divergent biology and liver microenvironment in HCC of metastatic and de novo origin. Mol Cancer, 25(1):(2026) [pubmed]

Dazert E, Colombi M, Boldanova T, Moes S, Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P, Hall MN, Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad Sci U S A, 113(5):1381-6(2016) [pubmed]

submitter keyword: Human, Super-SILAC, Sorafenib, (Phospho)-proteomics ((p)proteomics), Hepatocellular carcinoma (HCC), Biopsies

Michael N. Hall
contact affiliation	Biozentrum Basel, University of Basel, Basel, Switzerland
contact email	m.hall@unibas.ch
lab head
Eva Dazert
contact affiliation	Biozentrum University of Basel
contact email	eva.dazert@unibas.ch
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/04/PXD028593

PRIDE project URI

• PRIDE
  1. PXD028593
     1. Label: PRIDE project
     2. Name: (Phospho)-proteomic characterization of longitudinal biopsies from HCC patients treated with sorafenib